Press Releases

Our team at Pharmafocuseurope.com believes that press releases are an important marketing tool for highlighting a client's corporate message and ensuring it reaches their target audience. The feature can be used to publish business agreements, annual reports, financial results, corporate performances, important announcements, and any other important information that needs to be communicated to the target audience. Pharma companies can also use it to launch new products and promote existing ones.

Orchard Therapeutics Receives U.S. FDA Fast Track Designation for OTL-203 in MPS-IH

Saturday, December 02, 2023

Orchard Therapeutics a global gene therapy leader today announced the US Food and Drug Administration has granted Fast Track designation to OTL an investigational hematopoietic stem cell gene

AbbVie to Acquire ImmunoGen, including its Flagship Cancer Therapy ELAHERE® (mirvetuximab soravtansine-gynx), Expanding Solid Tumor Portfolio

Friday, December 01, 2023

AbbVie Inc NYSE ABBV and ImmunoGen Inc today announced a definitive agreement under which AbbVie will acquire ImmunoGen and its flagship cancer therapy ELAHERE

Alvotech Announces Positive Top-Line Results from a Pharmacokinetic Study for AVT05, a Proposed Biosimilar for Simponi® and Simponi Aria®

Thursday, November 30, 2023

Alvotech a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide announced today positive topline results from a pharmacokinetic

AbbVie Announces Positive Topline Results from Phase 2 LUMINOSITY Trial Evaluating Telisotuzumab-Vedotin for Patients with Previously Treated Non-Small Cell Lung Cancer

Thursday, November 30, 2023

AbbVie announced today topline results from the singlearm Phase LUMINOSITY trial evaluating telisotuzumabvedotin TelisoV in patients with cMet protein overexpression epidermal growth factor receptor

Carisma Therapeutics Announces FDA Clearance of IND Application for CT-0525, a Novel HER2-Targeting CAR-Monocyte

Wednesday, November 29, 2023

Carisma Therapeutics Inc a clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies today announced the clearance

Evaxion to Unveil Potentially Groundbreaking AI-Immunology™ Precision Cancer Vaccine Concept

Wednesday, November 29, 2023

Evaxion Biotech AS a clinicalstage TechBio company specializing in developing AIImmunology powered vaccines proudly announces the presentation

INmune Bio Receives EMA’s Authorization in France and Spain for Phase II Clinical Trial of XPro™ for Early Alzheimer’s Disease

Tuesday, November 28, 2023

INmune Bio Inc a clinical stage immunology company dedicated to advancing treatments that leverage the patients innate immune system to combat disease

SpringWorks Therapeutics Announces FDA Approval of OGSIVEO™ (nirogacestat) as the First and Only Treatment for Adults with Desmoid Tumors

Tuesday, November 28, 2023

SpringWorks Therapeutics Inc a commercialstage biopharmaceutical company focused on severe rare diseases and cancer announced today that the US Food and Drug Administration

Dupixent® Shows Promising Results in Second Phase 3 COPD Trial, Nearing FDA Submission as Potential First Approved Biologic

Monday, November 27, 2023

Regeneron Pharmaceuticals Inc and Sanofi today announced that the second Dupixent investigational Phase chronic obstructive pulmonary disease trial showed that Dupixent

Vertex Extends KAFTRIO® Application for Cystic Fibrosis and Rare Mutations with EMA Validation

Monday, November 27, 2023

Vertex Pharmaceuticals today announced that the European Medicines Agency has validated a Type II variation application to the Marketing Authorization for KAFTRIO